GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY22 results · Jul–Sep 2021
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹1,009.87 crore (up 14.8% from Q2 FY21) and net profit of ₹204.24 crore (up 167.1% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,009.87 | 879.32 | +14.8% | 789.99 | +27.8% |
| Other income | 14.97 | 9.04 | +65.6% | 31.73 | −52.8% |
| Total income | 1,024.84 | 888.36 | +15.4% | 821.72 | +24.7% |
| Profit before tax | 273.54 | 126.93 | +115.5% | 164.90 | +65.9% |
| Net profit for the period | 204.24 | 76.47 | +167.1% | 121.08 | +68.7% |
| EPS, basic (₹) | 12.06 | 4.51 | +167.4% | 7.15 | +68.7% |
| Net margin (%) | 20.2 | 8.7 | 15.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 991.53 | 879.39 | +12.8% | 773.46 | +28.2% |
| Other income | 15.05 | 8.92 | +68.7% | 31.73 | −52.6% |
| Total income | 1,006.58 | 888.31 | +13.3% | 805.19 | +25.0% |
| Profit before tax | 271.49 | 126.97 | +113.8% | 163.92 | +65.6% |
| Net profit for the period | 202.65 | 76.50 | +164.9% | 120.40 | +68.3% |
| EPS, basic (₹) | 11.96 | 4.52 | +164.6% | 7.11 | +68.2% |
| Net margin (%) | 20.4 | 8.7 | 15.6 |
Consolidated
- Filed with BSE
- 30 Oct 2021, 14:10 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2021, 14:10 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE